Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.

Chan M, Chang MC, González R, Lategan B, del Barco E, Vera-Badillo F, Quesada P, Goldstein R, Cruz I, Ocana A, Cruz JJ, Amir E.

PLoS One. 2015 Jul 10;10(7):e0132449. doi: 10.1371/journal.pone.0132449. eCollection 2015.

2.

Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M.

Ann Oncol. 2013 Mar;24(3):661-8. doi: 10.1093/annonc/mds430. Epub 2012 Sep 28.

PMID:
23022996
3.
4.
5.

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.

Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO.

J Clin Oncol. 2007 Oct 20;25(30):4772-8. Epub 2007 Sep 17.

PMID:
17876012
6.

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell'Orto P, Russo L, Szőke J, Doimi F, Villani L, Pizzolitto S, Öhlschlegel C, Sessa F, Peg Cámara V, Rodríguez Peralto JL, MacGrogan G, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G; SOFT and TEXT Investigators and International Breast Cancer Study Group.

Breast Cancer Res Treat. 2015 Nov;154(2):275-86. doi: 10.1007/s10549-015-3612-z. Epub 2015 Oct 22.

7.
8.

Impact of triple negative phenotype on breast cancer prognosis.

Kaplan HG, Malmgren JA.

Breast J. 2008 Sep-Oct;14(5):456-63. doi: 10.1111/j.1524-4741.2008.00622.x. Epub 2008 Jul 24.

PMID:
18657139
9.

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.

Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.

BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.

10.

Is triple negative a prognostic factor in breast cancer?

Nishimura R, Arima N.

Breast Cancer. 2008;15(4):303-8. doi: 10.1007/s12282-008-0042-3. Epub 2008 Mar 29.

PMID:
18369692
11.

Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.

Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA.

PLoS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946. Epub 2012 Jun 5.

12.

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A.

J Clin Oncol. 2008 Mar 1;26(7):1059-65. doi: 10.1200/JCO.2007.12.9437. Epub 2008 Jan 28.

PMID:
18227529
13.

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.

Kurozumi S, Matsumoto H, Hayashi Y, Tozuka K, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Kurosumi M.

BMC Cancer. 2017 May 22;17(1):354. doi: 10.1186/s12885-017-3331-4.

14.

Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.

Alqaisi A, Chen L, Romond E, Chambers M, Stevens M, Pasley G, Awasthi M, Massarweh S.

Breast Cancer Res Treat. 2014 Nov;148(2):437-44. doi: 10.1007/s10549-014-3145-x. Epub 2014 Sep 26.

PMID:
25257728
15.

Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status?

Wang N, Wang B, Wang Y, Hu J.

Breast. 2011 Dec;20(6):519-24. doi: 10.1016/j.breast.2011.05.009. Epub 2011 Jun 22.

PMID:
21700456
17.

Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.

Chen X, Yuan Y, Gu Z, Shen K.

Breast Cancer Res Treat. 2012 Aug;134(3):957-67. doi: 10.1007/s10549-012-1990-z. Epub 2012 Feb 28.

PMID:
22370627
18.

Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.

Balduzzi A, Bagnardi V, Rotmensz N, Dellapasqua S, Montagna E, Cardillo A, Viale G, Veronesi P, Intra M, Luini A, Pruneri G, Mastropasqua G, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2014 Aug;14(4):258-64. doi: 10.1016/j.clbc.2013.10.019. Epub 2013 Oct 26.

PMID:
24325948
19.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
20.

Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL; National Cancer Institute of Canada Clinical Trials Group MA.17.

J Clin Oncol. 2007 May 20;25(15):2006-11. Epub 2007 Apr 23.

PMID:
17452676

Supplemental Content

Support Center